KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T.
| Date | Est. | Actual | |
|---|---|---|---|
| May 15, 2026 | -$0.42 | -$1.08 | Miss |
| Mar 25, 2026 | -$0.54 | -$0.43 | Beat |
| Nov 10, 2025 | -$0.96 | -$0.92 | Beat |
| Sep 11, 2025 | -$0.91 | -$1.12 | Miss |
| Jul 10, 2025 | -$0.80 | -$0.99 | Miss |
| Mar 12, 2025 | -$0.89 | -$0.92 | Miss |